Supplementary Table S1 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Xin Jin,Yunqian Pan,Liguo Wang,Tao Ma,Lizhi Zhang,Amy H. Tang,Daniel D. Billadeau,Heshui Wu,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22414158.v1

2023-01-01

Abstract:Sequences for primers used for shRNAs and RT-qPCR

What problem does this paper attempt to address?

Supplementary Table S2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Xin Jin,Yunqian Pan,Liguo Wang,Tao Ma,Lizhi Zhang,Amy H. Tang,Daniel D. Billadeau,Heshui Wu,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22414155

2023-01-01

Abstract:FBP1-associated proteins identified by tandem affinity purification and mass spectrometry
Supplementary Materials and Methods from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Xin Jin,Yunqian Pan,Liguo Wang,Tao Ma,Lizhi Zhang,Amy H. Tang,Daniel D. Billadeau,Heshui Wu,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22414161

2023-01-01

Abstract:Supplementary Materials and Methods
Supplementary Figure 2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Xin Jin,Yunqian Pan,Liguo Wang,Tao Ma,Lizhi Zhang,Amy Tang,Daniel D. Billadeau,Heshui Wu,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22414164

2023-01-01

Abstract:Assessment of the effect of gemcitabine treatment on the cell cycle and interaction of IQGAP1 and ERK1/2 in PANC-1 cells.
Supplementary Primers and Shrna Information from DDR2 Coordinates EMT and Metabolic Reprogramming As a Shared Effector of FOXQ1 and SNAI1

Allison V. Mitchell,Jason Wu,Fanliang Meng,Dong Li,C. James Block,Won‐Min Song,Bin Zhang,Jing Li,Guojun Wu

DOI: https://doi.org/10.1158/2767-9764.22545699

2023-01-01

Abstract:Information of PCR primers for all gene tested and information for shRNA sequences for targeting several genes.
Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183960

2024-01-01

Abstract:Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.
Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Ling Li,Wenhua Tang,Xiaoqing Wu,David Karnak,Xiaojie Meng,Rachel Thompson,Xinbao Hao,Yongmin Li,Xiaotan T. Qiao,Jiayuh Lin,James Fuchs,Diane M. Simeone,Zhi-Nan Chen,Theodore S. Lawrence,Liang Xu

DOI: https://doi.org/10.1158/1078-0432.22446368.v1

2023-01-01

Abstract:PDF file - 112K, The sequences of the oligonucleotide primers used for qPCR (related to the qRT-PCR section of Materials and Methods).
Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Qing Cao,Zhengshuai Song,Hailong Ruan,Cheng Wang,Yan Xiong,Bingcheng Lin,Keshan Wang,Gong Chen,Tianbo Xu,Wen Xu,Xiong Zhang,Di Liu,Ming–Hsuan Yang,Diwei Zhou,Hongmei Yang,Ke Chen,Xiaoping Zhang

DOI: https://doi.org/10.1158/1078-0432.22473300.v1

2023-01-01

Abstract:Primers used in quantitative polymerase chain reaction for analysis of genomic amplification
Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191542

2024-01-01

Abstract:Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.
Supplementary Table S1 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Yong Li,Shunqun Luo,Ruihua Ma,Jing Liu,Pingwei Xu,Huafeng Zhang,Ke Tang,Jingwei Ma,Yi Zhang,Xiaoyu Liang,Yanling Sun,Tiantian Ji,Ning Wang,Bo Huang

DOI: https://doi.org/10.1158/0008-5472.22409990.v1

2023-01-01

Abstract:Supplementary Table S1. List of RT-PCR primers used.
Table S3 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling

Mingxiang Ye,Yong Zhang,Hongjun Gao,Yan Xu,Pengyu Jing,Jianxiong Wu,Xinxin Zhang,Jie Xiong,Chenfang Dong,Libo Yao,Jian Zhang

DOI: https://doi.org/10.1158/1078-0432.22464465

2023-01-01

Abstract:qPCR primer sequence (5'â†'3').
Supplementary Table S3. Primers and siRNAs from SPARC Stabilizes ApoE to Induce Cholesterol-Dependent Invasion and Sorafenib Resistance in Hepatocellular Carcinoma

Shan Wan,Quan-Yao He,Yun Yang,Feng Liu,Xue Zhang,Xin Guo,Hui Niu,Yi Wang,Yi-Xuan Liu,Wen-Long Ye,Xiu-Ming Li,Xue-Mei ZhuanSun,Pu Sun,Xiao-Shun He,Guang Hu,Kai Breuhahn,Hua Zhao,Guo-Qiang Wu,Hua Wu

DOI: https://doi.org/10.1158/0008-5472.25964444.v1

2024-01-01

Abstract:Supplementary Table S3. Primers and siRNAs
Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Yongheng Chen,Ying,Wenlong Ma,Hongchao Ma,Liang Shi,Xuefeng Gao,Min Jia,Meiqi Li,Xiaoman Song,Weixiao Kong,Wei Chen,Xiangyi Zheng,Tobias Achu Muluh,Xiaobin Wang,Maolin Wang,Xing-sheng Shu

DOI: https://doi.org/10.1158/0008-5472.25603759

2024-01-01

Abstract:Target sequences of shRNAs and sgRNAs used in this study.
Supplementary Table 1 from Valosin-Containing Protein Stabilizes Mutant P53 to Promote Pancreatic Cancer Growth

Jieqiong Wang,Yajie Chen,Canhua Huang,Quan Hao,Shelya X. Zeng,Sara Omari,Yu Zhang,Xiang Zhang,Hua Liu

DOI: https://doi.org/10.1158/0008-5472.22428753.v1

2023-01-01

Abstract:Supplementary Table S1 shows the sequences of siRNAs and the targeting sequences of high scored sgRNAs for CRISPR/Cas9.
Supplementary Tables from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Fei Huang,Qiaoni Shi,Yuzhen Li,Linlin Xu,Chi Xu,Fenfang Chen,Hai Wang,Hongwei Liao,Zai Chang,Fang Liu,Xiang H.-F. Zhang,Xin-Hua Feng,Jing-Dong J. Han,Shiwen Luo,Ye-Guang Chen

DOI: https://doi.org/10.1158/0008-5472.22420259

2023-01-01

Abstract:<p>Table S1 lists shRNA sequences from Sigma. Table S2 lists antibodies used in this study. Table S3 lists chemical inhibitors used in this study. Table S4 lists cell lines used in this study. Table S5 lists RT-qPCR primers and ChIP-qPCR primers used in this study</p>
Supplemental Tables from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Hong Zhu,Dan-Dan Wang,Tao Yuan,Fang-Jie Yan,Chen-Ming Zeng,Xiao-Yang Dai,Zi-bo Chen,Ying Chen,Tianyi Zhou,Guang-Han Fan,Meidan Ying,Ji Cao,Peihua Luo,Xi-Jie Liu,Yuandong Hu,Yong Peng,Qiaojun He,Bo Yang

DOI: https://doi.org/10.1158/0008-5472.22417223.v1

2023-01-01

Abstract:Supplemental Table 1. The primer sequences for qRT-PCR assay Supplemental Table 2. The targeting sequences for siRNA Supplemental Table 3. The list of compounds for YAP-TEADs luciferase screening
Supplementary Tables 1-7 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Chen Liang,Yi Qin,Bo Zhang,Shunrong Ji,Si Shi,Wenyan Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.1158/1541-7786.22512169

2023-01-01

Abstract:Supplementary Table S1. Primers sequences used in the real-time PCR. Supplementary Table S2. siRNA oligoes used in the study. Supplementary Table S3. Primers sequences used in the quantitative ChIP. Supplementary Table S4. Clinicopathological features and correlation of MUC16 expression in PDAC in the TCGA cohorts. Supplementary Table S5. Univariate and multivariate Cox regression of Overall survival for patients with PDAC in the TCGA cohorts. Supplementary Table S6. Clinicopathological features and correlation of MUC16 expression in PDAC in the FUSCC cohorts. Supplementary Table S7. Univariate and multivariate Cox regression of Overall survival for patients with PDAC in the FUSCC cohorts.
Figure S4 from Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models

Gang Yang,Wenfang Guan,Zhe Cao,Wenbo Guo,Guangbing Xiong,Fangyu Zhao,Mengyu Feng,Jiangdong Qiu,Yueze Liu,Michael Q. Zhang,Lei You,Taiping Zhang,Yupei Zhao,Jin Gu

DOI: https://doi.org/10.1158/1078-0432.22479591.v1

2023-01-01

Abstract:KEGG enrichment analysis for DEmRNAs
Data from N6-methyladenosine Modification of FZR1 Mrna Promotes Gemcitabine Resistance in Pancreatic Cancer

Jiachun Su,Rui Li,Ziming Chen,Shaoqiu Liu,Hongzhe Zhao,Shuang Deng,Lingxing Zeng,Zilan Xu,Sihan Zhao,Yifan Zhou,Mei Li,Xiaowei He,Ji Liu,Chunling Xue,Ruihong Bai,Lisha Zhuang,Quanbo Zhou,Shaoping Zhang,Rufu Chen,Xudong Huang,Dongxin Lin,Jian Zheng,Jialiang Zhang

DOI: https://doi.org/10.1158/0008-5472.c.6836996.v1

2023-01-01

Abstract:AbstractThe therapeutic options for treating pancreatic ductal adenocarcinoma (PDAC) are limited, and resistance to gemcitabine, a cornerstone of PDAC chemotherapy regimens, remains a major challenge. N6-methyladenosine (m6A) is a prevalent modification in mRNA that has been linked to diverse biological processes in human diseases. Herein, by characterizing the global m6A profile in a panel of gemcitabine-sensitive and gemcitabine-insensitive PDAC cells, we identified a key role for elevated m6A modification of the master G0–G1 regulator FZR1 in regulating gemcitabine sensitivity. Targeting FZR1 m6A modification augmented the response to gemcitabine treatment in gemcitabine-resistant PDAC cells both in vitro and in vivo. Mechanistically, GEMIN5 was identified as a novel m6A mediator that specifically bound to m6A-modified FZR1 and recruited the eIF3 translation initiation complex to accelerate FZR1 translation. FZR1 upregulation maintained the G0–G1 quiescent state and suppressed gemcitabine sensitivity in PDAC cells. Clinical analysis further demonstrated that both high levels of FZR1 m6A modification and FZR1 protein corresponded to poor response to gemcitabine. These findings reveal the critical function of m6A modification in regulating gemcitabine sensitivity in PDAC and identify the FZR1–GEMIN5 axis as a potential target to enhance gemcitabine response.Significance:Increased FZR1 translation induced by m6A modification engenders a gemcitabine-resistant phenotype by inducing a quiescent state and confers a targetable vulnerability to improve treatment response in PDAC.
Supplemental Tables from 14-3-3σ Contributes to Radioresistance by Regulating DNA Repair and Cell Cycle Via PARP1 and CHK2

Yifan Chen,Zhaomin Li,Dong Zhao,Jenny Beebe,Ke Yang,Liwu Fu,Jian‐Ting Zhang

DOI: https://doi.org/10.1158/1541-7786.22515373.v1

2023-01-01

Abstract:Supplemental Table S1. Sequence of shRNAs and siRNAs. Supplemental Table S2. Sequences of primers for real time RT-PCR.

Supplementary Table S1 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Supplementary Table S2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Supplementary Materials and Methods from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Supplementary Figure 2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Supplementary Primers and Shrna Information from DDR2 Coordinates EMT and Metabolic Reprogramming As a Shared Effector of FOXQ1 and SNAI1

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Table S3 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling

Supplementary Table S3. Primers and siRNAs from SPARC Stabilizes ApoE to Induce Cholesterol-Dependent Invasion and Sorafenib Resistance in Hepatocellular Carcinoma

Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Supplementary Table 1 from Valosin-Containing Protein Stabilizes Mutant P53 to Promote Pancreatic Cancer Growth

Supplementary Tables from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplemental Tables from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Supplementary Tables 1-7 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Figure S4 from Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models

Data from N6-methyladenosine Modification of FZR1 Mrna Promotes Gemcitabine Resistance in Pancreatic Cancer

Supplemental Tables from 14-3-3σ Contributes to Radioresistance by Regulating DNA Repair and Cell Cycle Via PARP1 and CHK2